phno
Small moleculeexperimental
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2010 (NCT01424449)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Dopamine D2 receptorAGONIST
DRD2 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- phno
- phno
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06261905 | Phase 1 | Mar 13, 2024 | University of Pennsylvania, Yale University |
| NCT03037060 | N/A | Dec 31, 2016 | University of Toronto |
| NCT02152670 | N/A | May 1, 2014 | Yale University |
| NCT01784016 | Phase 1 | Jan 1, 2014 | Mclean Hospital, National Institute on Drug Abuse (NIDA) |
| NCT01424449 | Phase 1 | Jan 1, 2010 | GlaxoSmithKline |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Yale University | Academic/Hospital | 2 | 2 | 2 | 2014 |
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2010 |
| Mclean Hospital | Academic/Hospital | 1 | 1 | 1 | 2014 |
| National Institute on Drug Abuse (NIDA) | Government | 1 | 0 | 1 | 2014 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2024 |
| University of Toronto | Academic/Hospital | 1 | 1 | 1 | 2016 |
6 organizations
Page 1 / 1